[A21-105] Pembrolizumab (colorectal cancer) - Addendum to Commission A21-36

Last updated 16.09.2021

Project no.:
A21-105

Commission:
Commission awarded on 10.08.2021 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

First-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer

Result of dossier assessment:

Unchanged after addendum:

  • Patients for whom intensive therapy is appropriate: hint of considerable added benefit.
  • Patients for whom intensive therapy is not appropriate: added benefit not proven.

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2021-09-16 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.